# Regeneron Pharmaceuticals
Who / What
Regeneron Pharmaceuticals, Inc. is an American biotechnology company specializing in the development and commercialization of innovative pharmaceutical products aimed at treating various diseases through advanced biologic therapies.
Background & History
Founded in 1988 in Westchester County, New York, Regeneron Pharmaceuticals emerged from a collaboration between scientists at Cornell University and Genentech. The company was established to advance research in biotechnology, particularly focusing on protein-based drugs. Over the decades, it has grown into a leader in the field of biologics, driven by breakthroughs in gene therapy, autoimmune diseases, and cancer treatment.
Why Notable
Regeneron is renowned for its groundbreaking contributions to medical science, including the development of key biologic therapies such as Eylea (aflibercept) for eye diseases and Pralnacase (pegloticase) for gout. The company’s innovative approach in gene therapy and precision medicine has positioned it as a critical player in advancing healthcare solutions globally.
In the News
Recently, Regeneron has been highlighted for its advancements in COVID-19 vaccine research, including collaborations with partners like Sanofi to develop antibody-based treatments. Additionally, its ongoing work in autoimmune diseases and cancer immunotherapy continues to capture media attention due to its potential to transform patient outcomes.
